» Articles » PMID: 15618458

Characterization of Fibroblast-specific Protein 1 in Pulmonary Fibrosis

Overview
Specialty Critical Care
Date 2004 Dec 25
PMID 15618458
Citations 110
Authors
Affiliations
Soon will be listed here.
Abstract

Because fibroblasts produce collagen and other extracellular matrix components that are deposited during tissue fibrosis, defining the behavior of these cells is critical to understanding the pathogenesis of fibrotic diseases. We investigated the utility of fibroblast-specific protein 1 (FSP1), a member of the calmodulin S100 troponin C superfamily, for identifying lung fibroblasts in a murine model of pulmonary fibrosis induced by intratracheal administration of bleomycin. Protein and mRNA expression of FSP1 was minimal in untreated lungs, but increased by 1 week after bleomycin administration and remained increased at 2 and 3 weeks after treatment. By immunohistochemistry, the number of FSP1(+) cells increased in a dose-dependent manner in the lungs after bleomycin treatment. Colocalization of alpha1 procollagen and FSP1 in interstitial cells demonstrated that FSP1(+) fibroblasts contribute to the deposition of collagen after bleomycin administration. In primary lung cell cultures, lung fibroblasts, but not macrophages or type II alveolar epithelial cells, expressed FSP1. FSP1 also identified fibroblasts in lung biopsy specimens from patients with documented usual interstitial pneumonitis. Therefore, FSP1 is an improved marker for lung fibroblasts that could be useful for investigating the pathogenesis of pulmonary fibrosis.

Citing Articles

Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects.

Cao Z, Quazi S, Arora S, Osellame L, Burvenich I, Janes P J Biomed Sci. 2025; 32(1):7.

PMID: 39780187 PMC: 11715488. DOI: 10.1186/s12929-024-01099-2.


Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer.

Tokhanbigli S, Haghi M, Dua K, Oliver B Cancer Drug Resist. 2024; 7:32.

PMID: 39403603 PMC: 11472577. DOI: 10.20517/cdr.2024.55.


[Ga]FAPI PET for Imaging and Treatment Monitoring in a Preclinical Model of Pulmonary Fibrosis: Comparison to [F]FDG PET and CT.

Ji H, Song X, Lv X, Shao F, Long Y, Song Y Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931393 PMC: 11206307. DOI: 10.3390/ph17060726.


Molecular and Genetic Biomarkers in Idiopathic Pulmonary Fibrosis: Where Are We Now?.

Tomos I, Roussis I, Matthaiou A, Dimakou K Biomedicines. 2023; 11(10).

PMID: 37893169 PMC: 10604739. DOI: 10.3390/biomedicines11102796.


Anti-S100A4 antibody administration alleviates bronchial epithelial-mesenchymal transition in asthmatic mice.

Liu S, Liu M, Zhong J, Chen S, Wang Z, Gao X Open Med (Wars). 2023; 18(1):20220622.

PMID: 37873538 PMC: 10590613. DOI: 10.1515/med-2022-0622.